12 Month Price Forecast For CLDX
Distance to CLDX Price Forecasts
CLDX Price Momentum
🤔 Considering Celldex (CLDX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 2:45 AM UTC
CLDX Analyst Ratings & Price Targets
Based on our analysis of 13 Wall Street analysts, CLDX has a consensus that is bullish. The median price target is $69.00, with forecasts ranging from $42.00 to $90.00. Currently, there are 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With CLDX currently trading at $24.24, the median price forecast suggests a 184.7% upside. The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 271.3% upside, while at provides the most conservative target, suggesting a 73.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLDX Analyst Consensus
CLDX Price Target Range
Latest CLDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 2, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Oct 28, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Oct 7, 2024 | Citigroup | David Lebowitz | Buy | Initiates | $70.00 |
| Sep 30, 2024 | Goldman Sachs | Richard Law | Neutral | Initiates | $45.00 |
| Sep 27, 2024 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $0.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Sep 25, 2024 | Wolfe Research | Andy Chen | Outperform | Reiterates | $51.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Sep 18, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Aug 12, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $37.00 |
| Jul 30, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Jul 30, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
Stocks Similar to Celldex Therapeutics Inc
The following stocks are similar to Celldex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Celldex Therapeutics Inc (CLDX) Financial Data
Celldex Therapeutics Inc has a market capitalization of $1.63B with a P/E ratio of -8.4x. The company generates $9.98M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +110.3% quarter-over-quarter, while maintaining an operating margin of -1,633.5% and return on equity of -29.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Celldex Therapeutics Inc (CLDX) Company Overview
About Celldex Therapeutics Inc
Develops therapeutic monoclonal and bispecific antibodies.
Celldex Therapeutics focuses on developing innovative antibody-based therapeutics aimed at treating a variety of diseases, including inflammatory and autoimmune conditions. The company generates revenue through the commercialization of its drug candidates and collaborations with research institutions, such as Yale University, which may include licensing agreements.
Founded in 1983 and based in Hampton, New Jersey, Celldex is at the forefront of biopharmaceutical research, with its lead drug candidate, CDX-0159, currently undergoing Phase II clinical trials. The company's strategic collaborations and advanced research initiatives position it well within the competitive landscape of therapeutic development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
160
CEO
Mr. Anthony S. Marucci M.B.A.
Country
United States
IPO Year
1990
Website
www.celldex.comCelldex Therapeutics Inc (CLDX) Latest News & Analysis
Celldex Therapeutics has begun a Phase 2 study of barzolvolimab for atopic dermatitis, a common skin disease affecting up to 20% of the U.S. population, and is currently enrolling patients.
Celldex's Phase 2 study of barzolvolimab in atopic dermatitis targets a prevalent condition, potentially expanding its market and driving growth if successful, impacting stock performance.
Celldex Therapeutics has initiated a Phase 1a study for CDX-622, a bispecific antibody, with the first patient dosed. The drug targets pathways related to chronic inflammation.
The dosing of the first patient in Celldex's CDX-622 study signals progress in drug development, potentially influencing future stock performance and investor sentiment regarding the company's pipeline.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) will participate in fireside chats at two upcoming conferences, as announced on November 11, 2024.
Management participation in conferences can signal potential developments or insights into Celldex's strategy, impacting investor sentiment and stock performance.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its Q3 2024 financial results and provided a corporate update on November 6, 2024.
Celldex's quarterly financial results and corporate update can influence stock performance, investor sentiment, and potential future funding or partnership opportunities.
Celldex Therapeutics (CLDX) reported a quarterly loss of $0.64 per share, better than the estimated loss of $0.69, and improved from a loss of $0.81 per share a year ago.
Celldex's smaller-than-expected quarterly loss indicates better financial performance and potential growth, which may boost investor confidence and influence stock price positively.
Celldex's Barzolvolimab, in Phase 3 for CSU, shows strong Phase 2 results but faces safety concerns. The company has a solid cash position, reducing dilution risks for pipeline development.
Celldex's Barzolvolimab shows promise in treating CSU, with Phase 2 success. Strong cash reserves mitigate dilution risks, crucial for sustaining pipeline development amid safety concerns.
Frequently Asked Questions About CLDX Stock
What is Celldex Therapeutics Inc's (CLDX) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Celldex Therapeutics Inc (CLDX) has a median price target of $69.00. The highest price target is $90.00 and the lowest is $42.00.
Is CLDX stock a good investment in 2025?
According to current analyst ratings, CLDX has 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CLDX stock?
Wall Street analysts predict CLDX stock could reach $69.00 in the next 12 months. This represents a 184.7% increase from the current price of $24.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Celldex Therapeutics Inc's business model?
Celldex Therapeutics focuses on developing innovative antibody-based therapeutics aimed at treating a variety of diseases, including inflammatory and autoimmune conditions. The company generates revenue through the commercialization of its drug candidates and collaborations with research institutions, such as Yale University, which may include licensing agreements.
What is the highest forecasted price for CLDX Celldex Therapeutics Inc?
The highest price target for CLDX is $90.00 from Yatin Suneja at Guggenheim, which represents a 271.3% increase from the current price of $24.24.
What is the lowest forecasted price for CLDX Celldex Therapeutics Inc?
The lowest price target for CLDX is $42.00 from at , which represents a 73.3% increase from the current price of $24.24.
What is the overall CLDX consensus from analysts for Celldex Therapeutics Inc?
The overall analyst consensus for CLDX is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $69.00.
How accurate are CLDX stock price projections?
Stock price projections, including those for Celldex Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
